Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923464 · ClinicalTrials.gov registry record
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
A clinical trial of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- 51
- Enrollment target
- 17
- Study locations
NCT04923464 is a study of Cystic Fibrosis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 51 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT04923464, a study of Cystic Fibrosis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully decentralized trial design.
Conditions Studied
Study Locations (17)
Other
- Birmingham Heartlands Hospital - Birmingham
- Royal Devon and Exeter Hospital - Exeter
- St. James University Hospital - Leeds
- Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital - London
- Wythenshawe Hospital - Manchester
- Southampton General Hospital - Southampton
Colorado
- National Jewish Health - Denver
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- Central Florida Pulmonary Group, P.A. - Orlando
Illinois
- Children's Hospital of Illinois at OSF Saint Francis Medical Center, Cystic Fibrosis Center - Peoria
Massachusetts
- Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Morristown Medical Center - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2021-12-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04923464
The ClinicalTrials.gov registry entry for NCT04923464 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (72% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT04923464 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Other, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04923464 about?
NCT04923464 is a clinical study titled "A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis". This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully decentralized trial design.
What is the current status of trial NCT04923464?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2021-06-30. Estimated completion is 2021-12-20.
What conditions does trial NCT04923464 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
Who is sponsoring clinical trial NCT04923464?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04923464 being conducted?
This trial has 17 study locations across Colorado, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.